{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:07:12Z","timestamp":1790024832760,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03395-1","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T22:50:50Z","timestamp":1731538250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-2119","authenticated-orcid":false,"given":"Stephanie V.","family":"Shimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-0511","authenticated-orcid":false,"given":"Paolo","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"3395_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","volume":"10","author":"N Morar","year":"2010","unstructured":"Morar N, Willis-Owen SA, Maurer T, Bunker CB (2010) HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 10:470\u2013478. https:\/\/doi.org\/10.1016\/S1473-3099(10)70101-8","journal-title":"Lancet Infect Dis"},{"key":"3395_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","volume":"62","author":"K Menon","year":"2010","unstructured":"Menon K, Van Voorhees AS, Bebo BF, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE (2010) Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 62:291\u2013299. https:\/\/doi.org\/10.1016\/j.jaad.2009.03.047","journal-title":"J Am Acad Dermatol"},{"key":"3395_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient. J Am Acad Dermatol 80:43\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.056","journal-title":"J Am Acad Dermatol"},{"key":"3395_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80:1029\u20131072. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057","journal-title":"J Am Acad Dermatol"},{"key":"3395_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23:60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid-Based Med"},{"key":"3395_CR6","unstructured":"Reddy SP, Lee E, Wu JJ Apremilast and Phototherapy for Treatment of Psoriasis in a Patient With Human Immunodeficiency Virus. 2"},{"key":"3395_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12719","volume":"31","author":"L Sacchelli","year":"2018","unstructured":"Sacchelli L, Patrizi A, Ferrara F, Bardazzi F (2018) Apremilast as therapeutic option in a HIV positive patient with severe psoriasis. Dermatol Ther 31:e12719. https:\/\/doi.org\/10.1111\/dth.12719","journal-title":"Dermatol Ther"},{"key":"3395_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/00325481.2019.1575613","volume":"131","author":"V Manfreda","year":"2019","unstructured":"Manfreda V, Esposito M, Campione E, Bianchi L, Giunta A (2019) Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgrad Med 131:239\u2013240. https:\/\/doi.org\/10.1080\/00325481.2019.1575613","journal-title":"Postgrad Med"},{"key":"3395_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/ijd.IJD_633_18","volume":"64","author":"BJ Shah","year":"2019","unstructured":"Shah BJ, Mistry D, Chaudhary N (2019) Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report. Indian J Dermatol 64:242\u2013244. https:\/\/doi.org\/10.4103\/ijd.IJD_633_18","journal-title":"Indian J Dermatol"},{"key":"3395_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X19845193","author":"M Zarbafian","year":"2019","unstructured":"Zarbafian M, Cote B, Richer V (2019) Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: a case report. SAGE Open Med Case Rep. https:\/\/doi.org\/10.1177\/2050313X19845193","journal-title":"SAGE Open Med Case Rep"},{"key":"3395_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14922","author":"A Agarwal","year":"2021","unstructured":"Agarwal A, Panda M, Ray A (2021) Complete remission of Psoriatic erythroderma using modified low dose etanercept in a HIV positive patient: a case report with review of literature. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.14922","journal-title":"Dermatol Ther"},{"key":"3395_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2475530320954279","volume":"6","author":"B Myers","year":"2021","unstructured":"Myers B, Thibodeaux Q, Reddy V, Chan S, Brownstone N, Liao W, Bhutani T (2021) Biologic treatment of 4 HIV-positive patients: a case series and literature review. J Psoriasis Psoriatic Arthritis 6:19\u201326. https:\/\/doi.org\/10.1177\/2475530320954279","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"3395_CR13","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2022.2416","author":"N Bernardini","year":"2022","unstructured":"Bernardini N, Skroza N, Tolino E (2022) HIV positive patient treated with ixekizumab. Clin Ter. https:\/\/doi.org\/10.7417\/CT.2022.2416","journal-title":"Clin Ter"},{"key":"3395_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000508781","volume":"12","author":"MCG Pangilinan","year":"2020","unstructured":"Pangilinan MCG, Sermswan P, Asawanonda P (2020) Use of anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol 12:132\u2013137. https:\/\/doi.org\/10.1159\/000508781","journal-title":"Case Rep Dermatol"},{"key":"3395_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ddg.13851","volume":"17","author":"V Di Lernia","year":"2019","unstructured":"Di Lernia V, Casanova DM, Garlassi E (2019) Secukinumab in an HIV-positive patient with psoriasis. JDDG J Dtsch Dermatol Ges 17:646\u2013648. https:\/\/doi.org\/10.1111\/ddg.13851","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"3395_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13895","author":"V Di Lernia","year":"2020","unstructured":"Di Lernia V, Casanova DM, Ricci C (2020) Brodalumab: another helpful option for HIV-positive psoriatic patients? Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.13895","journal-title":"Dermatol Ther"},{"key":"3395_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16494","author":"H Qin","year":"2022","unstructured":"Qin H, Lu J, Yi X, Ding Y, Shi Y (2022) Secukinumab treatment for a psoriasis patient co-infected with HIV and latent tuberculosis: a case report. J Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.16494","journal-title":"J Dermatol"},{"key":"3395_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15610","author":"P Romita","year":"2022","unstructured":"Romita P, Foti C, Calianno G, Chiricozzi A (2022) Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15610","journal-title":"Dermatol Ther"},{"key":"3395_CR19","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.2147\/CCID.S395348","volume":"15","author":"J Gong","year":"2022","unstructured":"Gong J, Wu W, Qiu L, Wang X, Bao J, Wang J, Cheng L, Fu Z, Hu F (2022) Interleukin-17A inhibitor secukinumab treatment in HIV-positive psoriasis patient: a case report. Clin Cosmet Investig Dermatol 15:2949\u20132956. https:\/\/doi.org\/10.2147\/CCID.S395348","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3395_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/ced.13630","volume":"44","author":"DM Wang","year":"2019","unstructured":"Wang DM, Fernandez AP, Calabrese CM, Calabrese LH (2019) Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin Exp Dermatol 44:113\u2013115. https:\/\/doi.org\/10.1111\/ced.13630","journal-title":"Clin Exp Dermatol"},{"key":"3395_CR21","unstructured":"Mu\u00f1oz LC, Mu\u00f1oz JP, Taboada AC, Casado AF, Bran EL Human Immunodeficiency Virus Infection in a Hepatitis B Virus\u2013 Positive Psoriasis Patient Treated With Ustekinumab. 2"},{"key":"3395_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2023.01.015","volume":"33","author":"K Maliyar","year":"2023","unstructured":"Maliyar K, Lansang P, Doiron P (2023) Use of risankizumab in two HIV-positive patients with psoriasis. JAAD Case Rep 33:54\u201355. https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.015","journal-title":"JAAD Case Rep"},{"key":"3395_CR23","doi-asserted-by":"publisher","DOI":"10.5070\/D32411041999","author":"G Bartos","year":"2018","unstructured":"Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR (2018) Current biological therapies for use in HIV-positive patients with psoriasis: case report of guselkumab used and review. Dermatol Online J. https:\/\/doi.org\/10.5070\/D32411041999","journal-title":"Dermatol Online J"},{"key":"3395_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15277","author":"F Rob","year":"2022","unstructured":"Rob F, Rozsypal H (2022) Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15277","journal-title":"Dermatol Ther"},{"key":"3395_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","volume":"28","author":"L Naldi","year":"2010","unstructured":"Naldi L (2010) Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol 28:88\u201392. https:\/\/doi.org\/10.1016\/j.clindermatol.2009.03.003","journal-title":"Clin Dermatol"},{"issue":"Suppl 2","key":"3395_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","volume":"25","author":"H Montaudi\u00e9","year":"2011","unstructured":"Montaudi\u00e9 H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Ma\u00eetre M, Misery L, Richard M-A, Ortonne J-P (2011) Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol JEADV 25(Suppl 2):12\u201318. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.03991.x","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"3395_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1269","author":"R Conway","year":"2015","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ (2015) Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.h1269","journal-title":"BMJ"},{"issue":"Suppl 2","key":"3395_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","volume":"25","author":"A Maza","year":"2011","unstructured":"Maza A, Montaudi\u00e9 H, Sbidian E, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Ma\u00eetre M, Misery L, Richard M-A, Ortonne J-P, Paul C (2011) Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol JEADV 25(Suppl 2):19\u201327. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.03992.x","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"3395_CR29","unstructured":"Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T Psoriasis Treatment in HIV-Positive Patients: A Systematic Review of Systemic Immunosuppressive Therapies. 6"},{"key":"3395_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG (2019) Psoriasis: Which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80:27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057","journal-title":"J Am Acad Dermatol"},{"key":"3395_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet Lond Engl 386:541\u2013551. https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8","journal-title":"Lancet Lond Engl"},{"key":"3395_CR32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour J-P, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A (2015) Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373:1318\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa1503824","journal-title":"N Engl J Med"},{"key":"3395_CR33","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","volume":"137","author":"ZK Jabbar-Lopez","year":"2017","unstructured":"Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH (2017) Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 137:1646\u20131654. https:\/\/doi.org\/10.1016\/j.jid.2017.04.009","journal-title":"J Invest Dermatol"},{"key":"3395_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, Tsai T-F, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C (2019) Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet 394:576\u2013586. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3","journal-title":"The Lancet"},{"key":"3395_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","volume":"11","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M (2021) Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther 11:885\u2013905. https:\/\/doi.org\/10.1007\/s13555-021-00511-1","journal-title":"Dermatol Ther"},{"key":"3395_CR36","first-page":"29","volume":"2","author":"JJ Emer","year":"2009","unstructured":"Emer JJ (2009) Is there a potential role for anti-tumor necrosis factor therapy in patients with human immunodeficiency virus? J Clin Aesthetic Dermatol 2:29\u201335","journal-title":"J Clin Aesthetic Dermatol"},{"key":"3395_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","volume":"74","author":"SM Gallitano","year":"2016","unstructured":"Gallitano SM, McDermott L, Brar K, Lowenstein E (2016) Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS. J Am Acad Dermatol 74:974\u2013980. https:\/\/doi.org\/10.1016\/j.jaad.2015.11.043","journal-title":"J Am Acad Dermatol"},{"key":"3395_CR38","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","volume":"159","author":"S Domm","year":"2008","unstructured":"Domm S, Cinatl J, Mrowietz U (2008) The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 159:1217\u20131228. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08851.x","journal-title":"Br J Dermatol"},{"key":"3395_CR39","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E (2021) Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol 157:1056\u20131065. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2599","journal-title":"JAMA Dermatol"},{"key":"3395_CR40","doi-asserted-by":"publisher","unstructured":"Kaminetsky J, Aziz M, Kaushik S (2018) A Review of Biologics and Other Treatment Modalities in HIV-Associated Psoriasis. Skin J Cutan Med https:\/\/doi.org\/10.25251\/skin.2.6.6","DOI":"10.25251\/skin.2.6.6"},{"key":"3395_CR41","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/jdv.12531","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Ito T, Hayashi M, Fukuchi O, Umezawa Y, Nobeyama Y, Teruya K, Nakagawa H (2015) Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol 29:1653\u20131655. https:\/\/doi.org\/10.1111\/jdv.12531","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3395_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3109\/09546634.2011.579085","volume":"23","author":"V Paparizos","year":"2012","unstructured":"Paparizos V, Rallis E, Kirsten L, Kyriakis K (2012) Ustekinumab for the treatment of HIV psoriasis. J Dermatol Treat 23:398\u2013399. https:\/\/doi.org\/10.3109\/09546634.2011.579085","journal-title":"J Dermatol Treat"},{"key":"3395_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/247553031420a00304","volume":"20","author":"S Wieder","year":"2014","unstructured":"Wieder S, Routt E, Levitt J, Lebwohl M (2014) Treatment of refractory psoriasis with ustekinumab in an HIV-positive patient: a case presentation and review of the biologic literature. Psoriasis Forum 20:96\u2013102. https:\/\/doi.org\/10.1177\/247553031420a00304","journal-title":"Psoriasis Forum"},{"key":"3395_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2340\/00015555-2698","volume":"97","author":"F Bardazzi","year":"2017","unstructured":"Bardazzi F, Magnano M, Campanati A, Loconsole F, Carpentieri A, Potenza C, Bernardini N, Di Lernia V, Carrera C, Raone B, Patrizi A, Loi C (2017) Biologic therapies in HIV-infected patients with psoriasis: an italian experience. Acta Derm Venereol 97:989\u2013990. https:\/\/doi.org\/10.2340\/00015555-2698","journal-title":"Acta Derm Venereol"},{"key":"3395_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13555-020-00373-z","volume":"10","author":"JJ Wu","year":"2020","unstructured":"Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M (2020) Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence. Dermatol Ther 10:351\u2013364. https:\/\/doi.org\/10.1007\/s13555-020-00373-z","journal-title":"Dermatol Ther"},{"key":"3395_CR46","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai T-F, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014) Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 371:326\u2013338. https:\/\/doi.org\/10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"3395_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","volume":"332","author":"A Puel","year":"2011","unstructured":"Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova J-L (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332:65\u201368. https:\/\/doi.org\/10.1126\/science.1200439","journal-title":"Science"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03395-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03395-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03395-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T23:05:23Z","timestamp":1731539123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03395-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03395-1","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This is a systematic review study. No ethics approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"14"}}